Abstract: The disclosed colorization system provides a wider, more continuous range of color options for virtual object colorization, supported by an intuitive user interface that simplifies user selection while maximizing customization possibilities. The colorization system provides continuous color ranges for virtual objects, using dynamically generated color ramps. In some implementations, the colorization systems provides two-dimensional (2D) color ramps that represent a continuous range of color options, that may be fully art-directed while also allowing for a wide range of color options than discrete options. The 2D color ramp can act as a source texture or gradient from which a near-infinite number of 1D color ramps can be dynamically derived based on user input.

Abstract: The present invention is directed to anti-activin antibodies, compositions comprising the same, and methods of using such antibodies and compositions for the prevention, diagnosis and treatment of a disease or disorder, such as, e.g., cancer, bone disease, cachexia, fibrotic disease, immune disorders, muscle atrophy, neurological diseases, renal diseases, reproductive diseases, and sarcopenia.

Abstract: The present invention is directed to anti-CTHRC1 fusion proteins, compositions comprising the same, and methods of using such anti-CTHRC1 fusion proteins and compositions for the prevention and/or treatment of cancer. Wherein anti-CTHRC1 fusion proteins comprise a first domain comprising a CTHRC1 binding moiety; and a second domain comprising a T cell engager; preferably wherein the T cell engager comprises a ligand for a receptor expressed on a T cell.

Abstract: Collagen Triple Helix Repeat Containing 1 (CTHRC1) was identified from a subtractive hybridization cDNA library, seeking genes associated with repair of arterial injury. The present invention is directed to anti-CTHRC1 antibodies, compositions comprising the same, and methods of using such antibodies and compositions for the prevention, diagnosis and treatment of a disease or disorder, such as, e.g., cancer, bone disease, fibrotic disease, arthritis, and osteoporosis.

Abstract: The disclosure provides compositions and methods comprising at least one TGF-0 inhibitor and at least one Activin inhibitor for use in methods of treating CAF-enriched cancers and/or fibrotic disease.

Abstract: Methods of treating infectious diseases, such as a viral diseases, and methods of enhancing the effectiveness of a vaccine against an infectious disease, such as a viral disease, with an ICOS agonist, such as an anti-ICOS agonist antibody, are provided.

Abstract: The invention provides methods of treating cancer and methods for selecting treatment approaches for cancer.

Abstract: Methods of treating cancer with particular doses of anti-ICOS antibodies are provided.

Abstract: Methods of treating cancer with multiple doses of anti-ICOS antibodies and multiple doses of anti-CTLA4 antibodies are provided.

Abstract: The invention provides methods of treating cancer and methods for selecting treatment approaches for cancer.

Abstract: The invention provides compositions and methods for the treatment of cancer and infectious diseases.

Abstract: The present disclosure provides methods of treating cancer and methods for selecting treatment approaches for cancer.

Abstract: Gene expression signatures correlating to ICOS expression levels are provided. Methods of treatment comprising determining ICOS expression levels using gene signatures in patients and administering anti-ICOS antibodies are also provided.

Abstract: Gene expression signatures correlating to ICOS expression levels are provided. Methods of treatment comprising determining ICOS expression levels using gene signatures in patients and administering anti-ICOS antibodies are also provided.

Abstract: The present disclosure provides, in part, compositions comprising peptides that immunospecifically bind to a defined binding partner, such as MHC class I polypeptide-related sequence A (MICA), or an epitope thereon. In some embodiments, the peptides comprise one or more complementarity determining regions relating to the complementarity regions shown in Table 1. The disclosure also provides methods of treating cancer in a subject using the compositions disclosed herein, and methods of isolating human antibodies from cancer patients following immunotherapy.

Abstract: The present disclosure provides, in part, compositions comprising peptides immuno specifically binds to defined binding partners, wherein the peptides comprise at least complementarity determining regions relating to the complementarity regions shown in Table 1.

Abstract: Methods of treating cancer with particular doses of anti-ICOS antibodies are provided.

Abstract: The invention provides methods of treating cancer and methods for selecting treatment approaches for cancer.

Abstract: A portable livestock sun shade that includes a base, a support material, a ballast container and a canopy. The support structure is mounted with respect to the base. The ballast container is mounted with respect to the base. The ballast container is adapted to receive a ballast material. The canopy is attached to the support structure. The canopy is capable of blocking at least a portion of solar rays. The canopy has an area that is greater than an area of the base.

Abstract: The present invention provides compositions and methods for treating cancer in a subject by eliciting an immune response against a MIC polypeptide.